- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.02. | Guggenheim raises PepGen stock price target to $7 on trial outlook | 2 | Investing.com | ||
| 08.12.25 | PepGen appoints Joseph Vittiglio as chief business and legal officer | 13 | Investing.com | ||
| 08.12.25 | PepGen Inc. - 8-K, Current Report | - | SEC Filings | ||
| PEPGEN Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | PepGen GAAP EPS of -$0.52 | 1 | Seeking Alpha | ||
| 12.11.25 | PepGen receives U.S. patent for myotonic dystrophy drug candidate | 18 | Investing.com | ||
| 12.11.25 | PepGen Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | PepGen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.10.25 | PepGen Inc.: PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society | 550 | Business Wire | PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and... ► Artikel lesen | |
| 26.09.25 | PepGen sichert sich 115 Millionen US-Dollar zur Finanzierung klinischer Studien | 9 | Investing.com Deutsch | ||
| 26.09.25 | PepGen raises $115 million in public offering to fund clinical trials | 4 | Investing.com | ||
| 26.09.25 | PepGen Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.09.25 | PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles | 8 | Benzinga.com | ||
| 25.09.25 | PepGen stock price target raised to $12 from $8 at H.C. Wainwright | 25 | Investing.com | ||
| 25.09.25 | Morning Market Movers: PepGen, 22nd Century Group, Immuneering, Transocean See Big Swings | 1.303 | AFX News | OTTAWA (dpa-AFX) - At 7:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 25.09.25 | PepGen stock soars after reporting highest splicing correction in DM1 patients | 4 | Investing.com | ||
| 25.09.25 | PepGen-Aktie explodiert nach Rekord-Studienergebnissen bei DM1-Patienten | 7 | Investing.com Deutsch | ||
| 25.09.25 | Why Did PepGen Shares Surge 120% After Hours? | 12 | Benzinga.com | ||
| 25.09.25 | PepGen announces pricing of $100M public offering | 3 | Seeking Alpha | ||
| 25.09.25 | PepGen prices common stock offering at $3.20 per share to raise $100m | 7 | Investing.com | ||
| 24.09.25 | PepGen reports positive DM1 treatment data with 53.7% splicing correction | 13 | Investing.com |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,10 | -0,21 % | BioNTech, Valneva oder BB Biotech: Warum es HIER in Kürze knallt! | Die Biotechbranche steht zu Beginn des Jahres 2026 erneut im Spannungsfeld zwischen wissenschaftlicher Innovation und wachsender Skepsis der Kapitalmärkte. Nach Jahren extremer Kursbewegungen prüfen... ► Artikel lesen | |
| AMGEN | 328,50 | -0,02 % | Is Amgen Stock Outperforming the Dow? | ||
| NOVAVAX | 8,495 | -0,97 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 162,45 | +0,06 % | WONBIOGEN Co., Ltd: Won BioGen Accelerates Global Market Expansion with Advanced Moist Wound Care Technology | SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Medical device manufacturer Won BioGen (CEO Kim Won-il) is accelerating its global market expansion based on its advanced moist wound care... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings | BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,500 | -2,60 % | Is Inovio Pharmaceuticals Stock Going to $0? | ||
| BIONXT SOLUTIONS | 0,386 | -1,28 % | BioNxt Solutions Inc.: BioNxt Announces Closing of Shares for Debt Settlement | VANCOUVER, BC / ACCESS Newswire / February 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that, further to its news release dated... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,340 | -1,19 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| MAINZ BIOMED | 0,748 | +2,78 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| INTELLIA THERAPEUTICS | 11,645 | -0,13 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites... ► Artikel lesen | |
| TEMPUS AI | 45,000 | -0,44 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,444 | +0,56 % | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,342 | -0,92 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 52,88 | +1,23 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,155 | -0,18 % | Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) |
Das Unternehmen PEPGEN INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,32 % bei einem Aktienkurs von 6,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PEPGEN INC finden Sie auf Wallstreet Online.